ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2332

Biomarkers for the Diagnosis and the Identification of Risk of Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA)

Claudia Bracaglia1, Denise Pires Marafon2, Ivan Caiello3, Kathy de Graaf4, Maria Ballabio4, Walter Ferlin4, Sergio Davì5, Grant Schulert6, Angelo Ravelli7, Alexei A. Grom8, Robert Nelson4, Cristina de Min4 and Fabrizio De Benedetti2, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 2Division of Rheumatology, IRCCS Bambino Gesù Children's Hospital, Rome, Rome, Italy, 3Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 4NovImmune S.A., Geneva, Switzerland, 5University of Genova, IRCCS Istituto Giannina Gaslini, Genoa, Italy, 6Pediatric Rheumatology, Division of Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 7University of Genova, IRCCS Istituto Giannina Gaslini, Genova, Italy, 8Division of Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States Minor Outlying Islands

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: cytokines, interferons and macrophage activation syndrome, Systemic JIA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Pediatric Rheumatology – Pathogenesis and Genetics Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: We have recently reported high levels of IFNγ and of the IFNγ-related chemokines, (CXCL9 and CXCL10) in patients with MAS (1).

Methods: Circulating levels of IFNγ, CXCL9, CXCL10, IL-18, neopterin and sCD25 IFNγ, CXCL9, CXCL10, IL-18, neopterin and sCD25 were measured by Luminex assay in 57 samples obtained from 24 patients with active sJIA and in 37 samples from 20 MAS patients with variable degrees of disease severity and under different treatments at time of sampling. We evaluated if blood levels of these biomarkers may help to identify sJIA patients with the predisposition to develop MAS, and additionally if they may help clinicians to distinguish MAS from active sJIA.

Results: Levels of IFNγ, CXCL9, CXCL10, IL-18, neopterin and sCD25 were significantly elevated in MAS compared to active sJIA without MAS at sampling (p-values <0.0001, except for IL-18 p=0.012) and were significantly correlated with laboratory parameters of disease severity, except for IL-18, whose levels were available only for a portion of the samples. During active sJIA without MAS at sampling, levels of the IFNγ-induced chemokines (CXCL9 and CXCL10) were significantly higher in patients with a history of MAS as compared to those of patients without a history of MAS (Table 1). In order to verify if measurement of these biomarkers could help in distinguishing MAS from active sJIA, we analyzed sensitivity and specificity and the area under the curve (AUC) for each parameter. The highest AUC (=0.95) was found for neopterin levels >14.62 nmol/L (Sensitivity 85.3% Specificity 84.6%). AUC for IFNγ (>8.5 pg/ml), CXCL9 (>2677 pg/ml), CXCL10 (>725.5 pg/ml), IL-18 >(4309 pg/ml) and sCD25 (>211.65 pg/ml) were 0.77, 0.82, 0.82, 0.82 and 0.86, respectively.

Table 1. Cytokine levels in sJIA patients with active disease with or without history of MAS

sJIA with history of MAS

(N=17)

sJIA without history of MAS

(N=40)

P

IFNγ (pg/ml)

5.6 (3.2-14.4)

5.3 (3.2-10)

0.74

CXCL9 (pg/ml)

3889 (965-7142)

519 (385-1168)

0.0015

CXCL10 (pg/ml)

764 (323-1259)

215 (152-470)

0.0003

IL-18 (pg/ml)

4405 (582-7122)

439 (312-824)

0.067

neopterin (nmol/L)

8.2 (6.5-13.9)

8.1 (6.6-8.8)

0.94

sCD25 (pg/ml)

80 (80-229)

80 (80-193)

1

Values are expressed as median (IQR)

Conclusion: Elevation of neopterin and CXCL9, both reflecting IFNγ production, and their correlation with laboratory parameters, supports the pathogenic role of IFNγ in MAS. Circulating levels of CXCL9 and CXCL10 (to a lesser extent of IL-18, though, not reaching statistical significance) are higher in patients with a history of MAS compared to patients without a history of MAS, suggesting subclinical activation of this pathway even in the absence of overt MAS and that CXCL9 and CXCL10 may identify patients at high risk for MAS; larger studies are needed. Regarding distinguishing MAS from active sJIA, levels of neopterin, IFNγ, CXCL9, CXCL10, sCD25, and IL-18 may be used and the possibility to integrate the currently available classification criteria with one or more of these biomarkers investigated in larger studies.

Reference. 1. Bracaglia C, et al. Ann Rheum Dis. 2017 Jan; 76(1):166-172.


Disclosure: C. Bracaglia, None; D. Pires Marafon, None; I. Caiello, None; K. de Graaf, Novimmune, 3; M. Ballabio, Novimmune, 3; W. Ferlin, Novimmune, 3; S. Davì, None; G. Schulert, None; A. Ravelli, None; A. A. Grom, NovImmune, Novartis Pharmaceutical Corporation, Roche Pharmaceuticals, 2; R. Nelson, NovImmune, 3; C. de Min, NovImmune, 3; F. De Benedetti, Novartis, Roche, Pfizer, SOBI, AbbVie, Novimmune, BMS, Sanofi, 2.

To cite this abstract in AMA style:

Bracaglia C, Pires Marafon D, Caiello I, de Graaf K, Ballabio M, Ferlin W, Davì S, Schulert G, Ravelli A, Grom AA, Nelson R, de Min C, De Benedetti F. Biomarkers for the Diagnosis and the Identification of Risk of Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA) [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/biomarkers-for-the-diagnosis-and-the-identification-of-risk-of-macrophage-activation-syndrome-mas-in-systemic-juvenile-idiopathic-arthritis-sjia/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/biomarkers-for-the-diagnosis-and-the-identification-of-risk-of-macrophage-activation-syndrome-mas-in-systemic-juvenile-idiopathic-arthritis-sjia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology